



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 22141

Title: Hepatic Decompensation/Serious Adverse Events in Post-OLT recipients on Sofosbuvir for Recurrent HCV

Reviewer's code: 00181532

Reviewer's country: United States

Science editor: Yuan Qi

Date sent for review: 2015-08-18 10:08

Date reviewed: 2015-09-13 20:58

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

In this manuscript, the authors reported disappointingly low SVR rates (overall SVR rate 45%) in a small cohort of post-OLT patients receiving sofosbuvir and ribavirin for recurrent HCV infection. Minor comments: Page 5, line 7: 63% should be 62% Page 6, second paragraph: Despite its pangenotypic property, sofosbuvir was originally approved by FDA for genotypes 1-4 HCV infection. Please verify that. Page 8: Please mention the full name of EOT when it first appears in text. Page 10, line 14: eGFR should be added after 'estimated glomerular filtration rate' here Page 10, line 15: [OR =0.95, p =0.01] and [OR =2.43 per mg/dL, p<0.01] Page 12, line 11: 'direct acting antivirals' should be changed to 'DAAs'